Every 8-K that 60 Degrees Pharmaceuticals, Inc. Warrant (SXTPW) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow SXTPW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SXTPW filings page.
60 Degrees Pharmaceuticals, Inc. (SXTP) reported results for the first five patients to complete tafenoquine-containing combination treatment in its expanded access study of relapsing babesiosis in immunosuppressed patients. All five reported being much or very much improved and had negative conventional PCR results during treatment or follow-up. Four of five (80%) had nonreactive post-treatment blood-donor NAT results; the fifth had a reactive NAT despite a negative follow-up conventional PCR. NAT samples were collected 66–120 days after treatment.
Two additional patients remain on treatment, bringing enrollment to seven; the study remains open pending potential FDA discussions. The company expects to unblind its separate randomized, placebo-controlled hospitalized-patient study in January 2027 and then intends to request a pre-sNDA meeting. It plans to pursue accelerated approval if its efficacy dossier is based primarily on data from immunosuppressed patients with relapsing babesiosis. Tafenoquine is not FDA-approved to treat or prevent babesiosis, and the company cautioned that the small uncontrolled study and historical case comparisons may not predict outcomes in larger studies.
60 Degrees Pharmaceuticals, Inc. updated its investor presentation on tafenoquine development for babesiosis, covering chronic, relapsing and severe acute programs. Tafenoquine is not approved by FDA or EMA for babesiosis; the presentation lists approved uses for malaria prevention and single-dose radical cure of P. vivax malaria with chloroquine.
The randomized hospital study enrolled 30 subjects, remains blinded, and has follow-up completion and unblinding planned for January 2027. Three expanded-access patients had post-treatment NAT-negative results; outcomes for two others were pending. In the chronic B-FREE screening, 2 of 9 patients were positive on genus-level dPCR; 0 of 9 were positive on B. microti NAT and 0 of 9 on Mayo species-specific PCR, and no enrolled patient had yet qualified for the primary per-protocol analysis. A pre-sNDA meeting was planned for late January 2027. The presentation describes a potential sNDA in 2027, with the lead regulatory path depending on the hospital-study result, and a September 2026 request for national-priority review.
The presentation identifies substantial doubt about the company's ability to continue as a going concern as a risk.
60 Degrees Pharmaceuticals (SXTP) has suspended further enrollment in its randomized severe-babesiosis study and intends to finalize the analysis with the 30 subjects enrolled as of October 1, 2026. It plans to unblind the study and report primary and secondary endpoint results in January 2027. The DSMB recommended completing the originally planned enrollment of 33 patients; the company cites marginal impact from three additional patients and seasonal enrollment that could delay unblinding by a year.
The DSMB analysis identified no safety issues, but did not establish whether the study met its endpoints. The company plans to request a pre-sNDA meeting with FDA in January 2027. It also reported molecular cure, using a sensitive NAT, in the first three patients in its expanded-access study; screening data for two additional patients are expected in early November 2026. Any accelerated-approval pathway is subject to FDA review. The company states substantial doubt about its ability to continue as a going concern.
60 DEGREES PHARMACEUTICALS, INC. (SXTP) reports that on September 12, 2026 it submitted a Statement of Interest to the FDA requesting a Commissioner’s National Priority Voucher for an efficacy supplement to NDA 210607 for ARAKODA (tafenoquine) to treat babesiosis, a tick-borne parasitic disease with no FDA-approved therapy. The company highlights published case reports in treatment‑refractory babesiosis showing cure rates of about 83% when tafenoquine is added to atovaquone-based therapy, and confirms that all three currently evaluable patients in its FDA‑authorized expanded access study have been cured.
The company is conducting a randomized, double‑blind, placebo‑controlled trial (NCT06207370), with enrollment for a prespecified interim analysis complete and a DSMB review scheduled for October 1, 2026. Depending on that outcome, it plans either regular approval based on the trial or accelerated approval supported by expanded‑access and published data, targeting an sNDA submission in March–April 2027. The company states that CNPV review could allow tafenoquine to become the first FDA‑approved babesiosis treatment by or before the 2027 tick season, and it commits to manufacture more than 50% of the value of any CNPV‑supported products in the U.S. and to provide volume‑based discounts to federal programs.
60 Degrees Pharmaceuticals, Inc. (SXTP) furnished an updated investor presentation outlining its strategy to expand the label of its marketed antimalarial ARAKODA® (tafenoquine) from malaria prophylaxis into babesiosis and other tick-borne diseases. The presentation highlights non-clinical data, human case-series signals, and a planned staged regulatory path toward a potential sNDA in babesiosis, including an interim analysis on October 6, 2026 and subsequent FDA interactions.
The company reports Q2 2026 net product revenue of $208k, up 106% year over year, with gross profit of $57k and about 27% gross margin. A July 31, 2026 private placement raised approximately $1 in gross proceeds at $1.74 per share or pre-funded warrant, contributing to liquidity of about $1 cash and equivalents as of June 30, 2026 and operating cash use of about $5 over the prior six months, supporting runway into early October 2026. The company also discloses that there is substantial doubt about its ability to continue as a going concern and positions babesiosis as a potentially larger value driver, with an estimated $180M opportunity that could help triple the ARAKODA® asset value if successfully developed and approved.
60 Degrees Pharmaceuticals, Inc. held its virtual 2026 annual stockholders meeting on August 5, 2026. As of the July 2, 2026 record date, 2,659,288 shares of common stock were outstanding. Holders of 1,107,592 shares, about 41.6% of the voting shares, were represented in person or by proxy, establishing a quorum pursuant to the Delaware General Corporation Law and the company’s amended and restated bylaws.
Stockholders cast more votes “for” than “withheld” for each of the five director nominees, including Geoffrey Dow (147,223 for; 25,031 withheld) and Eric Francois (141,202 for; 31,052 withheld), with 935,338 broker non-votes on each election. For each additional proposal on the agenda, the required affirmative vote of a majority of shares represented at the meeting was achieved, and each proposal was approved, with reported “for” votes ranging from 92,303 to 997,089.
60 Degrees Pharmaceuticals entered into securities purchase agreements with institutional investors on July 30, 2026 for a private placement priced at-the-market under Nasdaq rules. The company is issuing 191,571 shares of common stock at $1.74 per share and pre-funded warrants for 383,142 shares at $1.739, together with Series A and Series B common stock warrants.
The transaction covers a total of 574,713 common shares (or pre-funded warrants) plus Series A and short-term Series B warrants to purchase up to 574,713 shares each, all with an exercise price of $1.49 per share. Gross proceeds are approximately $1.0 million, before fees and expenses, with intended use for working capital, general operations and the company’s research and development program.
Pre-funded warrants are exercisable immediately at $0.001 per share and remain outstanding until fully exercised. The Series A warrants expire five years after the effective date of a resale registration statement and the Series B warrants after 24 months, and both are subject to a Beneficial Ownership Limitation generally capping holders at 4.99% or, at their election, 9.99% of outstanding common stock. H.C. Wainwright & Co. receives a 7.5% cash fee, a 1.0% management fee, expense reimbursements and warrants to purchase 43,103 shares at $2.175 per share. The unregistered securities rely on Section 4(a)(2) and Rule 506 of Regulation D, and the company has agreed to file resale registration statements using best efforts within 45 days of July 30, 2026, or 75 days if subject to full SEC review.
60 Degrees Pharmaceuticals, Inc. furnished an updated investor presentation describing its strategy to develop and commercialize products for vector-borne diseases. The company’s lead product is ARAKODA (tafenoquine), an FDA-approved malaria prophylaxis since 2018 targeting a stated $50–70M U.S. malaria prevention market.
The presentation outlines plans to expand tafenoquine into babesiosis, including FDA orphan-drug status granted in 2024 and multiple clinical programs: a randomized hospital study in acute babesiosis with an interim analysis planned after at least 24 patients by late 2026, an expanded-access study in relapsing immunosuppressed patients, and a Phase II open-label study in chronic babesiosis.
Management highlights intellectual property with four Orange Book-listed U.S. patents for tafenoquine expiring in December 2035, recent equity financing (a $5M public offering and about $4M raised via an at-the-market program), and 2.66 million common shares outstanding as of March 31, 2026. The risk discussion includes substantial doubt about the company’s ability to continue as a going concern, dependence on clinical success, eligibility for research incentives, and reliance on third-party manufacturing.
60 Degrees Pharmaceuticals outlined its statistical analysis plan for an interim look at its randomized, placebo-controlled trial of tafenoquine in patients hospitalized with severe babesiosis. An interim analysis is planned for the earlier of October 30, 2026 or after 24 of 33 planned patients have been randomized and followed for at least 50 days.
The plan uses conditional power analyses for time to sustained clinical resolution and time to molecular cure, with potential early reporting or sample size increase up to 66 patients. As of this notice, 23 patients had been enrolled. If results support an sNDA, the company aims to pursue a Commissioner’s National Priority Review Voucher before the end of the first quarter of 2028.
60 Degrees Pharmaceuticals, Inc. states that it intends to apply for a Commissioner’s National Priority Review Voucher if data from its randomized, placebo-controlled trial of tafenoquine in patients hospitalized with severe babesiosis support submitting a New Drug Application to the U.S. Food and Drug Administration before the end of the first quarter of 2028.
The company explains that this plan reflects its current development and regulatory strategy and emphasizes that expectations about the trial, any future NDA filing, and any voucher application are forward-looking and subject to risks, including clinical outcomes, regulatory interactions, and broader market and risk factors described in its Form 10-K and Form 10-Q filings.
60 Degrees Pharmaceuticals, Inc. reported that its Board of Directors appointed Eric Francois as a director, effective May 13, 2026. He is a veteran healthcare and life sciences financial executive with over 20 years of experience in investment banking, corporate finance, and board roles.
Francois has held senior positions at Raymond James and Credit Suisse, leading equity, debt, and M&A transactions for biotechnology companies. He also previously served as Chief Financial Officer of SCYNEXIS, Inc., where he raised over $300 million in capital and supported the company through FDA approval and commercial launch. He has prior public company board and committee experience and will receive standard non-employee director compensation, with no special arrangements, family relationships, or related-party transactions disclosed.
60 Degrees Pharmaceuticals, Inc. filed a Form 8-K to correct an error in previously disclosed share ownership for a company affiliate. A March 13, 2026 prospectus supplement had shown the affiliate as beneficially owning 21,490 shares; the correct figure is 23,367 shares. The error traces back to an incorrect total in a Form 4 dated September 15, 2025 that was carried into a December 16, 2025 Form 4 and then into the prospectus disclosure. After giving effect to the 1-for-4 reverse stock split, the corrected total number of shares beneficially owned is 16,781 instead of 15,905. The company states that no other information in the prospectus supplement is affected.
60 Degrees Pharmaceuticals, Inc. filed a Form 8-K to note that it obtained and filed an updated legal opinion from its counsel covering shares of common stock issued and sold under its existing at-the-market equity offering program with HC Wainwright & Co., LLC.
The company states that this opinion does not change the terms of the at-the-market program. Instead, it confirms the validity of shares that may be sold under the program and addresses certain legal matters related to those sales under applicable law.
60 Degrees Pharmaceuticals, Inc. reported that it has regained compliance with Nasdaq’s minimum bid price requirement of $1.00 per share under Listing Rule 5550(a)(2). Nasdaq’s Listing Qualifications Staff confirmed the company now meets all Nasdaq Capital Market listing standards.
The company had previously received a delisting notice after its stock traded below $1.00 for 30 consecutive business days and paid a $20,000 hearing fee to appeal. With compliance restored, the February 19, 2026 Nasdaq Hearings Panel session has been cancelled, the delisting matter is closed, and the company’s common stock and warrants will continue to trade on The Nasdaq Capital Market.
60 Degrees Pharmaceuticals, Inc. (SXTP) reports that Nasdaq staff has determined to delist its common stock and warrants from The Nasdaq Capital Market. Nasdaq concluded the company failed to maintain the required minimum bid price of $1.00 per share for 30 consecutive business days under Listing Rule 5550(a)(2), and that it is not eligible for the usual 180‑day grace period because it completed a 1‑for‑5 reverse stock split on February 24, 2025 under Listing Rule 5810(c)(3)(A)(iv). The company’s warrants are also subject to delisting under Listing Rule 5560(a) because the underlying common stock is subject to delisting. The company has paid a $20,000 hearing fee and requested an appeal to a Nasdaq hearings panel, which temporarily stays any trading suspension and the filing of a Form 25‑NSE until the panel issues its decision.
60 Degrees Pharmaceuticals, Inc. approved a reverse stock split of its common stock at a final ratio of one-for-four. The company’s stockholders approved the amendment to its Certificate of Incorporation on October 8, 2025, after a recommendation from the board of directors. The company then filed a Certificate of Amendment in Delaware on January 14, 2026, which becomes effective at 12:01 a.m. Eastern Time on January 20, 2026.
At the effective time, every four shares of issued and outstanding common stock are automatically combined and converted into one share. The company is not issuing fractional shares; any fractional amounts are rounded up to one whole share. The company also issued a press release about the reverse split on January 15, 2026, which is included as an exhibit.
60 Degrees Pharmaceuticals, Inc. filed a current report to share that its Chief Executive Officer, Geoffrey Dow, is scheduled to provide investor information beginning on September 9, 2025. The company prepared an investor presentation for this event, which is included as Exhibit 99.1 to the report.
The materials in the presentation are stated to be current as of September 9, 2025, and the company notes it does not undertake to update this information in the future. The presentation is furnished under Regulation FD, meaning it is provided for informational purposes and is not treated as filed for liability purposes under certain securities laws.
60 Degrees Pharmaceuticals, Inc. reported an item on an 8-K disclosing a Sales Agreement dated September 5, 2025 between the company and H.C. Wainwright & Co., LLC related to its securities. The filing lists the Sales Agreement as Exhibit 1.1 and includes a legal opinion and consent from Sichenzia Ross Ference Carmel LLP as Exhibits 5.1 and 23.1. The document is signed by Geoffrey Dow, Chief Executive Officer and President.
The filing supplies exhibit-level detail but does not disclose the economic terms, offering size, pricing mechanics, or expected timing for any sales under the agreement. No financial tables, revenue, or earnings data are provided.